OncoCyte (OCX)
(Delayed Data from NSDQ)
$3.12 USD
+0.01 (0.32%)
Updated Aug 26, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for OncoCyte Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -27.78 | -72.90 | -64.10 | -29.93 | -22.43 |
Depreciation/Amortization & Depletion | 1.68 | 23.92 | 4.26 | 2.50 | 0.45 |
Net Change from Assets/Liabilities | -3.97 | -0.63 | -2.20 | 0.40 | -1.56 |
Net Cash from Discontinued Operations | 1.52 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.23 | 4.04 | 26.10 | 1.06 | 3.82 |
Net Cash From Operating Activities | -23.33 | -45.57 | -35.94 | -25.98 | -19.72 |
Property & Equipment | 0.07 | -4.34 | -2.25 | -1.23 | -0.92 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -11.71 | -6.19 | 0.00 |
Investments | 0.37 | 0.00 | 0.00 | -4.00 | -11.25 |
Other Investing Activities | -1.37 | 0.00 | 0.00 | -0.33 | -0.25 |
Net Cash from Investing Activities | -0.93 | -4.34 | -13.96 | -11.75 | -12.42 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 12.73 | 37.72 | 82.96 | 22.18 | 49.79 |
Issuance (Repayment) of Debt | -0.12 | -1.43 | -1.53 | 0.70 | 1.88 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.43 | -0.48 | -3.07 | -0.07 | -3.80 |
Net Cash from Financing Activities | 12.19 | 35.81 | 78.36 | 22.80 | 47.87 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -12.07 | -14.10 | 28.46 | -14.93 | 15.74 |
Cash at Beginning of Period | 23.20 | 37.31 | 8.84 | 23.77 | 8.03 |
Cash at End of Period | 11.13 | 23.20 | 37.31 | 8.84 | 23.77 |
Diluted Net EPS | -3.75 | -13.20 | -14.40 | -9.20 | -8.80 |
Fiscal Year End for OncoCyte Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -13.66 | -9.13 | -27.78 | -11.79 | -5.30 |
Depreciation/Amortization & Depletion | 0.66 | 0.34 | 1.68 | 1.36 | 5.88 |
Net Change from Assets/Liabilities | -0.16 | 1.02 | -3.97 | -3.46 | -3.57 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 1.52 | 1.66 | 0.15 |
Other Operating Activities | 3.35 | 3.95 | 5.23 | -6.53 | -13.66 |
Net Cash From Operating Activities | -9.81 | -3.83 | -23.33 | -18.76 | -16.50 |
Property & Equipment | -0.22 | -0.02 | 0.07 | 0.34 | 0.12 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.37 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -1.37 | -1.51 | 0.00 |
Net Cash from Investing Activities | -0.22 | -0.02 | -0.93 | -1.17 | 0.12 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 10.42 | 0.00 | 12.73 | 12.73 | 12.30 |
Issuance (Repayment) of Debt | -0.03 | 0.00 | -0.12 | -0.09 | -0.06 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.54 | 0.00 | -0.43 | -0.43 | 0.00 |
Net Cash from Financing Activities | 9.85 | 0.00 | 12.19 | 12.22 | 12.25 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.18 | -3.85 | -12.07 | -7.72 | -4.14 |
Cash at Beginning of Period | 11.13 | 11.13 | 23.20 | 23.20 | 23.20 |
Cash at End of Period | 10.96 | 7.28 | 11.13 | 15.48 | 19.07 |
Diluted Net EPS | -0.36 | -1.13 | -2.27 | -0.81 | -1.07 |